Colistin: Revival of an Old Polymyxin Antibiotic

Therapeutic Drug Monitoring

Volumn 37, Issue 4, 2015, Pages 419-427

  Dijkmans, Anneke C ^a,c   Wilms, Erik B ^b,d   Kamerling, Ingrid M C ^c   Birkhoff, Willem ^c   Ortiz Zacarías, Natalia V ^c   Van Nieuwkoop, Cees ^d   Verbrugh, Henri A ^a,e   Touw, Daan J ^f  

^a MEDICAL CENTER HAAGLANDEN   (Netherlands)

^b Central Pharmacy for The Hague Hospitals   (Netherlands)

^c CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^d HAGA HOSPITAL   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

antimicrobial activity; colistimethate sodium; colistin; pharmacology

Indexed keywords

COLISTIMETHATE; COLISTIN; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL PRACTICE; DRUG FORMULATION; DRUG MECHANISM; DRUG MONITORING; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PROCEDURES;

ANTI-BACTERIAL AGENTS; COLISTIN; DRUG MONITORING; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84937930886     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000172     Document Type: Review

References (87)

1. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol. 1929;10:226-236.
2. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6:589-601.
3. Morel CM, Mossialos E. Stoking the antibiotic pipeline. BMJ. 2010;340: c2115.
4. Bergen PJ, Landersdorfer CB, Zhang J, et al. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis. 2012;74:213-223.
5. Westerman EM, Le Brun PP, Touw DJ, et al. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros. 2004;3:23-28.
6. Wright WW, Welch H. Chemical, biological and clinical observations on colistin. Antibiot Annu. 1959;7:61-74.
7. Geus JP. Behandeling van infecties door gram-negatieve bacteriën met colistine (Colimycine). Ned Tijdschr Geneeskd. 1961;105:669.
8. Yahav D, Farbman L, Leibovici L, et al. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect. 2012;18:18-29.
9. Velkov T, Thompson PE. Structure-activity relationships of polymyxin antibiotics. J Med Chem. 2009;53:1898-1916.
10. Newton BA. The properties and mode of action of the polymyxins. Bacteriol Rev. 1956;20:14-27.
11. Peterson AA, Hancock RE, McGroarty EJ. Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa. J Bacteriol. 1985;164:1256-1261.
12. Zhang L, Dhillon P, Yan H. Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2000;44:3317-3321.
13. Schindler PR, Teuber M. Action of polymyxin B on bacterial membranes: morphological changes in the cytoplasm and in the outer membrane of Salmonella typhimurium and Escherichia coli B. Antimicrob Agents Chemother. 1975;8:95-104.
14. Chen CCH, Feingold DS. Locus of divalent cation inhibition of the bactericidal action of polymyxin B. Antimicrob Agents Chemother. 1972;2:331-335.
15. Davis SD, Iannetta A, Wedgwood RJ. Activity of colistin against pseudomonas aeruginosa: inhibition by calcium. J Infect Dis. 1971;124:610-612.
16. Baeuerlein A. Transepithelial activation of human leukocytes by probiotics and commensal bacteria: role of Enterobacteriaceae-type endotoxin. Microbiol Immunol. 2009;53:241-250.
17. Senturk S. Evaluation of the anti-endotoxic effects of polymyxin-E (colistin) in dogs with naturally occurred endotoxic shock. J Vet Pharmacol Ther. 2005;28:57-63.
18. Antimicrobial Susceptibility Testing: Breakpoints 2013: European Committee on Antimicrobial Susceptibilty Testing EUCAST; 2013.
19. CLSI. Performance standards for antimicrobial susceptibility testing: Twenty Second Informational Supplement M100-S22. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2012.
20. Colistin is extensively Lost during Normal Experimental conditions. Available at: http://www.abstractsonline.com/plan/ViewAbstract.aspx? mID=2789&sKey=7504fdb1-3935-4908-96f9-9460e52bbec9&cKey= 985ade82-9618-4ec1-b893-7fa42500121f&mKey=0c918954-d607-46a7-8073-44f4b537a439.
21. Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol. 2013;51:1678-1684.
22. Sader HS, Rhomberg PR, Flamm RK, et al. Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin. Diagn Microbiol Infect Dis. 2012;74:412-414.
23. Clinical Laboratory testing and in vitro diagnostic test systems-Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices-Part 1: reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. Geneva: International Standards Organisation; 1-1-2013.
24. Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother. 2009;53: 3628-3634.
25. Koch-Weser J, Sidel VW, Federman EB, et al. Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med. 1970;72:857-868.
26. Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother. 2010;54:4971-4977.
27. Bergen PJ, Landersdorfer CB, Zhang J. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new? Diagn Microbiol Infect Dis. 2012;74:213-223.
28. Westerman EM, Le Brun PPH, Touw DJ, et al. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros. 2004;3:23-28.
29. Cai Y, Chai D, Wang R, et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67:1607-1615.
30. Barrow K, Kwon DH. Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.
31. Fernandez L, Gooderham WJ, Bains M, et al. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParRParS. Antimicrob Agents Chemother. 2010;54:3372-3382.
32. Fernandez L, Jensen H, Bains M, et al. The two-component system CprRS senses cationic peptides and triggers adaptive resistance in Pseudomonas acruginosa independently of ParRS. Antimicrob Agents Chemother. 2012;56:6212-6222.
33. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53:879-884.
34. Gauthier TP, Wolowich WR, Reddy A, et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother. 2012;56:2392-2396.
35. Sorli L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380.
36. Mizuyachi K, Hara K, Wakamatsu A, et al. Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects. Curr Med Res Opin. 2011;27:2261-2270.
37. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720-1726.
38. Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care. 2003;7:R78-R83.
39. Michalopoulos AS, Tsiodras S, Rellos K, et al. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gramnegative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect. 2005;11:115-121.
40. Kasiakou SK, Michalopoulos A, Soteriades ES, et al. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother. 2005;49:3136-3146.
41. Giamarellou H, Poulakou G. Multidrug-resistant gram-negative infections. Drugs. 2009;69:1879-1901.
42. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27.
43. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003;36:1111-1118.
44. Bergen PJ, Landersdorfer CB, Lee HJ, et al. 'Old' antibiotics for emerging multidrug-resistant bacteria. Curr Opin Infect Dis. 2012;25:626-633.
45. Marchand S, Lamarche I, Gobin P, et al. Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J Antimicrob Chemother. 2010;65:1753-1758.
46. Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents. 2005;25:11-25.
47. Li J, Milne RW, Nation RL, et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;761:167-175.
48. Gobin P, Lemaitre F, Marchand S, et al. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2010;54:1941-1948.
49. Li J, Milne RW, Nation RL, et al. Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother. 2003; 47:1766-1770.
50. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284-3294.
51. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gramnegative bacteria. Antimicrob Agents Chemother. 2009;53:3430-3436.
52. Couet W, Gregoire N, Gobin P, et al. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther. 2011;89:875-879.
53. Li J, Milne RW, Nation RL, et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother. 2004;53:837-840.
54. Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56:4241-4249.
55. Chen G, Thamlikitkul V, Jacob J, et al. Plasma protein binding of colistin in critically-ill patients receiving intravenous colistin methanesulfonate. abstract A2-1178. Paper presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology; September 17-20, 2011; Chicago, IL. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=8df031f3-1992-47c5-9a73-0a9ea6581faa&cKey=00762a70-08d3-4227-8c86-f5bc3b40e083&mKey=0c918954-d607-46a7-8073-44f4b537a439.
56. Bergen PJ, Bulitta JB, Forrest A, et al. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother. 2010;54:3783-3789.
57. Dudhani RV, Turnidge JD, Nation RL, et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother. 2010;65:1984-1990.
58. Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother. 2009;53:4907-4910.
59. Markou N, Fousteri M, Markantonis SL, et al. Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium. Chest. 2011;139:232-233.
60. Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010;138:1333-1339.
61. Pryor JG, Apt L, Leopold IH. Intraocular penetration of colistin. Arch Ophthalmol. 1962;67:612-615.
62. Ratjen F, Rietschel E, Kasel D, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother. 2006;57:306-311.
63. Yapa WS, Li J, Patel K, et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother. 2014;58:2570-2579.
64. Athanassa ZE, Markantonis SL, Fousteri MZ, et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 2012;38:1779-1786.
65. Akers KS, Rowan MP, Niece KL, et al. Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration. 2014 Oct 13 pii: AAC.03783-14. [Epub ahead of print].
66. Bode-Boger SM, Schopp B, Troger U, et al. Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring. Int J Antimicrob Agents. 2013;42:357-360.
67. Koomanachai P. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 2014.
68. Dalfino L, Puntillo F, Mosca A, et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis. 2012;54:1720-1726.
69. Daikos GL, Skiada A, Pavleas J, et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother. 2010;22:175-178.
70. Halaby T, Al NN, Kluytmans J, et al. Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother. 2013;57:3224-3229.
71. SmPC ColiFin PARI 1 MIU Powder for solution for inhalation. Germany: PARI Pharma GmbH; 2014.
72. SmPC colomycin injection. England: Forest Laboratories UK Ltd.; 1-11-2012.
73. SmPC Coly-mycin M parenteral. NDA 50-108/S-026. Rochester, USA: Parkedale Pharmaceuticals, Inc.; 2006.
74. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med. 2007;357:2310-2311.
75. Markou N, Fousteri M, Markantonis SL, et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother. 2012;67:2459-2462.
76. Karvanen M, Plachouras D, Friberg LE, et al. Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother. 2013;57:668-671.
77. Koomanachai P, Landersdorfer CB, Chen G, et al. Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 2014;58:440-446.
78. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010;65:1019-1027.
79. Zusman O, Avni T, Leibovici L, et al. Systematic review and metaanalysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother. 2013;57:5104-5111.
80. Lee HJ, Bergen PJ, Bulitta JB, et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother. 2013;57:3738-3745.
81. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57:349-358.
82. Huang DB, Pastagia M, Chiang T. Challenges to conducting a clinical trial of combination therapy of colistin and rifampicin for extensively drugresistant Acinetobacter baumannii. Clin Infect Dis. 2014;58:141-142.
83. Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30:1279-1291.
84. Cai Y, Li R, Liang B, et al. In vitro antimicrobial activity and mutant prevention concentration of colistin against Acinetobacter baumannii. Antimicrob Agents Chemother. 2010;54:3998-3999.
85. Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis. 2005;5:1.
86. Chen L, Mediavilla JR, Endimiani A, et al. Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (bla KPC) variants. J Clin Microbiol. 2011;49:579-585.
87. Samenvatting van de produktkenmerken. Tadim Colisnemethaatnatrium poeder voor infusie 1 MIE; RVG 109891;Profile Pharma Ltd;Clinchester, West Sussex, UK: 8-11-2011.; 8-11-2011.